Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that all-too-familiar routine of meetings and deadlines and what-not has returned. You knew this would happen, though. To cope, we are chugging cups of stimulation and, as always, invite you to join us. Remember: no prescription is required. Meanwhile, here are some tidbits. Have a wonderful day and do stay in touch …

Merck and Samsung Bioepis on Monday will launch a biosimilar version of Remicade in the U.S. for treating rheumatoid arthritis and Crohn’s disease, among other ailments. The list price will be about $753.39, which amounts to a 35 percent discount to the brand-name drug that is marketed by Johnson & Johnson. However, J&J already sells its drug at a 30 percent discount from its own list price. Last fall, Pfizer began selling a biosimilar version of Remicade at a 15 percent discount.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!